Topline results from the study are anticipated in the first half of 2027.
News|Articles|April 1, 2025
FDA updates in urology: March 2025
Author(s)Hannah Clarke
A recap of the FDA submissions and regulatory decisions in urology from March 2025.
Advertisement
Advertisement
Welcome to Urology Times’® monthly FDA update! This month, key developments include the initiation of a pivotal trial in stress urinary incontinence (SUI), an expanded indication for radioligand therapy in metastatic castration-resistant prostate cancer (mCRPC), and the approval of a new treatment regimen in muscle-invasive bladder cancer (MIBC).
Related to this article
Chad R. Ritch, MD, MBA, FACS, discusses how PSMA-PET informs staging, treatment planning, recurrence workup, and the interpretation of equivocal findings.
Brian I. Rini, MD, FASCO, explains why LITESPARK-012’s negative triplet results still offer lessons on drug delivery and building on first-line RCC doublets.
JNJ-6143 demonstrated promising PSA and tumor response rates with an encouraging safety profile in heavily pretreated mCRPC, including across genomic subgroups.
Alberto Briganti, MD, PhD, discusses results from the PROTEUS substudy, evaluating perioperative apalutamide plus ADT vs surgery alone in high-risk localized or locally advanced prostate cancer.
In a POTOMAC subgroup analysis, durvalumab plus BCG reduced the risk of high-risk recurrence or death by 44% vs BCG alone in patients with papillary-only, BCG-naive NMIBC.
Updated CAPItello-281 data showed a clinically meaningful benefit in OS when capivasertib was added to abiraterone and ADT in PTEN-deficient mHSPC.
Andrea Necchi, MD, discusses how results from the CA017-078 trials compares with other perioperative immunotherapy trials in muscle-invasive bladder cancer.
Advertisement
Advertisement